Valuation : Glenmark Pharmaceuticals Limited

Market Cap 697B 7.35B 6.34B 5.96B 5.43B 10.21B 10.27B 70.46B 27.43B 355B 27.58B 26.98B 1,176B P/E 2027 *
30x
P/E 2028 * 25x
Enterprise Value 661B 6.96B 6B 5.65B 5.15B 9.68B 9.73B 66.77B 25.99B 336B 26.14B 25.57B 1,114B EV / Sales 2027 *
3.93x
EV / Sales 2028 * 3.47x
Free-Float
51.04%
Yield 2027 *
0.15%
Yield 2028 * 0.16%
1 day-1.03%
1 week+3.25%
Current month-1.03%
1 month+10.34%
3 months+8.35%
6 months+15.27%
Current year+21.04%
1 week 2,385.75
Extreme 2385.75
2,536.85
1 month 2,163
Extreme 2163
2,536.85
Current year 1,842.8
Extreme 1842.8
2,536.85
1 year 1,794
Extreme 1794
2,536.85
3 years 702.05
Extreme 702.05
2,536.85
5 years 348.9
Extreme 348.9
2,536.85
10 years 168
Extreme 168
2,536.85
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 86 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%+3.25% - - 7.36B
-2.81%+0.99%+20.98%+73.53% 50.05B
+1.14%+1.47%+59.54%+123.40% 40.29B
+0.56%+5.80%+19.04%+86.59% 12.17B
+0.98%-1.04%-10.47%+13.15% 11.96B
+0.57%+2.72%+31.59%+153.11% 9.25B
-0.15%-1.65%+27.65%+48.56% 7.62B
-0.39%+3.33%+28.41%+222.15% 7.36B
+1.43%+1.70%+50.00%-9.99% 7.21B
-0.13%+0.79%-36.70%+15.26% 5.26B
Average +0.02%+1.16%+21.11%+80.64% 16.8B
Weighted average by Cap. -0.46%+1.81%+29.33%+87.93%

Financials

2027 *2028 *
Net sales 168B 1.77B 1.53B 1.44B 1.31B 2.46B 2.47B 16.97B 6.61B 85.42B 6.64B 6.5B 283B 187B 1.97B 1.7B 1.6B 1.46B 2.74B 2.76B 18.91B 7.36B 95.19B 7.4B 7.24B 316B
Net income 23.11B 244M 210M 198M 180M 338M 340M 2.34B 909M 11.76B 914M 894M 38.98B 27.71B 292M 252M 237M 216M 406M 408M 2.8B 1.09B 14.09B 1.1B 1.07B 46.73B
Net Debt -36.49B -384M -332M -312M -284M -534M -537M -3.69B -1.44B -18.56B -1.44B -1.41B -61.55B -48B -506M -436M -410M -374M -703M -707M -4.85B -1.89B -24.42B -1.9B -1.86B -80.97B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
01/09/26 2,464.20 -1.03% 17,692
31/08/26 ₹2,489.85 -1.09% 38,805
28/08/26 ₹2,517.40 +2.50% 19,900
27/08/26 ₹2,456.00 +0.66% 17,019
26/08/26 ₹2,440.00 +1.88% 12,072
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,470.40INR
Average target price
2,497.73INR
Spread / Average Target
+1.11%

Quarterly revenue - Rate of surprise